Abstract: A head-mounted display device includes a see-though display providing both eyes of a user with a view of a physical object, a processor, and a non-volatile storage device holding instructions executable by the processor to: display an image that corresponds to the physical object to a first eye of the user at an offset to the physical object; display blocking light to a second eye of the user; in response to alignment user input, move a position of the image relative to the physical object; in response to completion user input, determine the inter-pupillary distance of the user; and calibrate the head-mounted display device based on the inter-pupillary distance.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: Disclosed are diagnostics kits and compositions for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.

Abstract: Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI), assessment of the amount of neuronal damage, and/or susceptibility to neurodegenerative disease in a subject.

Abstract: A head-mounted display device includes a see-though display providing both eyes of a user with a view of a physical object, a processor, and a non-volatile storage device holding instructions executable by the processor to: display an image that corresponds to the physical object to a first eye of the user at an offset to the physical object; display blocking light to a second eye of the user; in response to alignment user input, move a position of the image relative to the physical object; in response to completion user input, determine the inter-pupillary distance of the user; and calibrate the head-mounted display device based on the inter-pupillary distance.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: Disclosed are diagnostics for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.

Abstract: A head-mounted display device is disclosed that includes an at least partially see-though display, a processor, and a non-volatile storage device holding instructions executable by the processor to: select an image that corresponds to a physical object viewable by the user; display the image at a perceived offset to the physical object; in response to alignment user input, move a perceived position of the image relative to the physical object; output an instruction to provide completion user input when the image appears to align with the physical object; when the completion user input is received, determine the inter-pupillary distance of the user; and calibrate the head mounted display device based on the inter-pupillary distance.

Abstract: A fertilizer composition, comprising solid granules each including a homogeneous blend of ammonium sulfate, a water insoluble oxide of a micronutrient metal, and a water-soluble sulfate of the micronutrient metal. A method of forming a fertilizer composition, comprising the steps of: combining ammonium sulfate and a water insoluble oxide of a micronutrient metal; granulating the ammonium sulfate and water insoluble oxide of the micronutrient metal in the presence of a liquid to initiate reaction of a portion of the ammonium sulfate with a portion of the water insoluble oxide of the micronutrient metal to form ammonia and a water-soluble sulfate of the micronutrient metal; and producing a fertilizer composition in the form of solid fertilizer granules each comprising a homogeneous blend of ammonium sulfate, the water insoluble oxide of the micronutrient metal, and the water-soluble sulfate of the micronutrient metal.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

Abstract: The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI), assessment of the amount of neuronal damage, and/or susceptibility to neurodegenerative disease in a subject.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: The invention provides diagnostic tests to distinguish between different pre-symptomatic neurodegenerative diseases.

Abstract: Disclosed are diagnostics for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.